Clinical Trial Update: First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating first-line icotinib with concurrent radiotherapy in EGFR-mutant non-small cell lung cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN